Early access eyed for experimental 'Triple G' weight-loss drug ahead of FDA decision

Retatrutide (a.k.a. 'Triple G')—an experimental weight-loss drug from Eli Lilly that mimics GLP-1, GIP, and glucagon—has shown substantially greater weight loss than current medications, with trial results reporting up to about 28% body-weight reduction over 80 weeks and additional A1C improvements. Lilly plans an FDA filing in early 2027, potentially a year-long review. Meanwhile, compassionate-use access has raised questions about eligibility, and a regulatory clash over whether retatrutide is a biologic or a peptide could affect exclusivity and future availability.